Drugs / Magnesium Pidolate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00143572 | Nov 2004 → Jan 2008 | sickle cell disease | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06261320 | Feb 2024 → Dec 2026 expected | inflammatory bowel disease | Polyclinique de l'Europe | Active not recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00532883 Comparator | Jan 2007 → Mar 2009 | sickle cell-hemoglobin c disease syndrome | St. Jude Children's Research Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01181830 Comparator | Feb 2010 → Dec 2012 | metabolic syndrome X | University of Verona | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Magnesium Pidolate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00143572 ↗ |
| Route | Oral | “oral supplements of 8.1 mmol of magnesium-pidolate or placebo were administered twice a day to 14 healthy normomagnesemic participants, aged 23-33 years” PMID 24984823 ↗ May 2014 |